

Looking Forward



The Next Generation of Biosimilars

Biosimilars are a type of biological product approved by FDA on the basis of being highly similar to an already approved biological reference product. This panel of experts will discuss the current state of biosimilars in the healthcare ecosystem and what comes next from a technical and legal perspective.

Panelists

- Jennifer DiGiacinto, RRD International
- Robert S. Langer, MIT; Consultant, Eagle Biologics
- Benjamin Roin, MIT Sloan School of Management
- Moderator: Aaron S. Kesselheim, Brigham and Women's Hospital/ Harvard Medical School

February 7, 2017, 12:00pm

Wasserstein Hall, Milstein East A (2036), Harvard Law School



Sponsored by the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School and Eagle Biologics.

This event is free and open to the public. Learn more and register at <http://petrieflom.law.harvard.edu/events>.